GlaxoSmithKline Pharmaceuticals Limited GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited

GLAXO

株式のランク #3644
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
株価
$27.54
最終同期: 2026-10-19
時価総額
$4.67B
変化(1日)
-2.73%
変化(1年)
-12.13%
国
IN
取引 GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

カテゴリー

Healthcare
GlaxoSmithKline Pharmaceuticals Limited(GLAXO)の利益
Jun 2026 時点の利益 TTM: $159.96M
GlaxoSmithKline Pharmaceuticals Limited の最新の財務報告によると、同社の現在の利益は $159.96M です。2024 年には $97.88M の利益を上げ、これは 2023 年の利益 $101.78M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
GlaxoSmithKline Pharmaceuticals Limited の利益の推移(2004 〜 2026)
各年末の利益
年 利益 変化
2026 (TTM) $159.96M 8.59%
2025 $147.31M 50.49%
2024 $97.88M -3.82%
2023 $101.78M -0.83%
2022 $102.63M 65.48%
2021 $62.02M 52.81%
2020 $40.59M -58.72%
2019 $98.31M 18.54%
2018 $82.93M 5.21%
2017 $78.83M -9.71%
2016 $87.30M -9.89%
2015 $96.88M -0.90%
2013 $97.77M -35.64%
2012 $151.90M -13.05%
2011 $174.69M -10.43%
2010 $195.02M 19.11%
2009 $163.74M 13.31%
2008 $144.51M -9.37%
2007 $159.46M 24.82%
2006 $127.75M 17.87%
2005 $108.38M 10.05%
2004 $98.49M 0.00%
同業他社の利益
企業 利益 利益の差 国
$33.60B 20,902.13%
US
$17.74B 10,988.20%
US
$8.70B 5,338.14%
US
$5.95B 3,618.36%
US
$21.39B 13,270.79%
CH